title: Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy?
abstract: BACKGROUND
  A growing number of treatment options exist to treat metastatic castrate-resistant prostate cancer (mCRPC), and with these newer options, many questions about optimising treatment remain unanswered. One recommendation that may potentially be overlooked by practitioners is that androgen deprivation therapy (ADT) should be maintained when CRPC develops and when treatment with any of the newer agents is initiated.
  
  
  OBJECTIVE
  However, to emphasise this recommendation, it is valuable to interrogate the evidence for maintaining ADT in different clinical situations.
  
  
  RESULTS
  This statement, reflecting the views of the authors, provides a discussion of this evidence and the rationale behind the recommendation that ADT should be continued in CRPC.
authors.affiliation: Department of Urology and Urologic Oncology, Hannover Medical School, Hannover, Germany.
authors.forename: Axel S
authors.initials: AS
authors.lastname: Merseburger
authors.forename: Peter
authors.initials: P
authors.lastname: Hammerer
authors.forename: Francois
authors.initials: F
authors.lastname: Rozet
authors.forename: Thierry
authors.initials: T
authors.lastname: Roumeguère
authors.forename: Orazio
authors.initials: O
authors.lastname: Caffo
authors.forename: Fernando Calais
authors.initials: FC
authors.lastname: da Silva
authors.forename: Antonio
authors.initials: A
authors.lastname: Alcaraz
mesh_terms: D000736:Androstenes / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001549:Benzamides; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D016729:Leuprolide / Q000627:therapeutic use*; D008297:Male; D009570:Nitriles; D009919:Orchiectomy; D010669:Phenylthiohydantoin / Q000031:analogs & derivatives / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D064129:Prostatic Neoplasms, Castration-Resistant / Q000628:therapy*; D011868:Radioisotopes / Q000627:therapeutic use; D011883:Radium / Q000627:therapeutic use; D043823:Taxoids / Q000627:therapeutic use; D014020:Tissue Extracts / Q000627:therapeutic use
chemical_list: D000736:Androstenes; D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D001549:Benzamides; D009570:Nitriles; D011868:Radioisotopes; D043823:Taxoids; D014020:Tissue Extracts; D010669:Phenylthiohydantoin; D007987:Gonadotropin-Releasing Hormone; C552428:cabazitaxel; C511774:sipuleucel-T; C540278:enzalutamide; D016729:Leuprolide; C089740:abiraterone; C581106:radium Ra 223 dichloride; D011883:Radium